AnteoTech Ltd (ASX: ADO) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Anteotech Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $439.47 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 1.95 billion
Earnings per share -0.002
Dividend per share N/A
Year To Date Return 119.05%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

AnteoTech Ltd (ASX: ADO)
Latest News

ADO ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About AnteoTech Ltd

AnteoTech Ltd is a biotechnology company engaged in the development of specialty products and services and end-user diagnostic products focused on the Battery and Life Science diagnostics markets. Its keys areas are Energy and Life ScienceDivision. The company is developing three products named AnteoCoat, AnteoBind, and AnteoRelease, all of these products are used in the energy, diagnostic, and medical device markets. The company currently has a single segment which is the development of the Anteo Intellectual property.

ADO Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
30 Jul 2021 $0.23 $-0.01 -4.35% 3,513,460 $0.23 $0.24 $0.23
29 Jul 2021 $0.23 $0.00 0.00% 4,160,114 $0.23 $0.24 $0.23
28 Jul 2021 $0.23 $0.01 4.44% 8,100,885 $0.24 $0.25 $0.22
27 Jul 2021 $0.23 $0.02 9.52% 7,562,347 $0.22 $0.23 $0.20
26 Jul 2021 $0.21 $-0.02 -8.89% 3,967,599 $0.23 $0.24 $0.21
23 Jul 2021 $0.23 $-0.01 -4.35% 1,670,685 $0.23 $0.24 $0.23
22 Jul 2021 $0.23 $0.01 4.44% 3,145,134 $0.23 $0.24 $0.22
21 Jul 2021 $0.23 $-0.01 -4.35% 4,195,688 $0.24 $0.25 $0.23
20 Jul 2021 $0.23 $0.00 0.00% 7,131,640 $0.22 $0.24 $0.22
19 Jul 2021 $0.23 $-0.01 -4.17% 11,006,426 $0.26 $0.26 $0.22
16 Jul 2021 $0.24 $0.01 4.26% 3,512,556 $0.24 $0.25 $0.23
15 Jul 2021 $0.24 $-0.02 -8.00% 3,697,791 $0.25 $0.26 $0.23
14 Jul 2021 $0.25 $0.00 0.00% 2,710,155 $0.25 $0.26 $0.25
13 Jul 2021 $0.25 $0.01 4.17% 1,557,576 $0.24 $0.25 $0.24
12 Jul 2021 $0.24 $-0.01 -4.00% 1,829,652 $0.25 $0.25 $0.24
09 Jul 2021 $0.25 $-0.01 -3.92% 2,146,602 $0.25 $0.25 $0.24
08 Jul 2021 $0.26 $0.01 4.00% 3,579,085 $0.26 $0.26 $0.24
07 Jul 2021 $0.25 $-0.01 -3.92% 2,151,958 $0.26 $0.26 $0.25
06 Jul 2021 $0.26 $0.01 4.00% 2,354,206 $0.26 $0.27 $0.26
05 Jul 2021 $0.25 $-0.01 -3.85% 2,818,237 $0.27 $0.27 $0.25
02 Jul 2021 $0.26 $0.01 3.92% 3,112,261 $0.27 $0.27 $0.25
01 Jul 2021 $0.26 $0.00 0.00% 3,901,906 $0.26 $0.27 $0.25

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
25 May 2021 Geoffrey Cumming Sell 17 $4,515
As advised by the company. Withdrawal of SPP application (at $0.26 per share)
25 May 2021 Geoffrey Cumming Buy 17 $4,515
Participation in share purchase plan.
25 May 2021 John (Jack) Hamilton Sell 24 $6,257
As advised by the company. Withdrawal of SPP application (at $0.26 per share)
25 May 2021 John (Jack) Hamilton Buy 24 $6,257
Participation in share purchase plan.
25 May 2021 Christopher Parker Sell 17 $4,515
As advised by the company. Withdrawal of SPP application (at $0.26 per share)
25 May 2021 Christopher Parker Buy 17 $4,515
Participation in share purchase plan.
27 Nov 2020 Geoffrey Cumming Sell 1 $128,901
On-market trade.
23 Nov 2020 Matthew (Matt) Sanderson Buy 2 $52,569
Exercise of options.
23 Nov 2020 Matthew (Matt) Sanderson Exercise 2 $52,569
Exercise of options.
16 Nov 2020 John (Jack) Hamilton Exercise 5 $117,736
Exercise of options.
16 Nov 2020 John (Jack) Hamilton Issued 2 $216,000
Issue of options.
16 Nov 2020 John (Jack) Hamilton Issued 5 $117,736
Exercise of options.
12 Nov 2020 Geoffrey Cumming Issued 1 $127,500
Issue of options.
12 Nov 2020 Matthew (Matt) Sanderson Issued 1 $127,500
Issue of options.
12 Nov 2020 Christopher Parker Issued 1 $127,500
Issue of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Geoffrey James Cumming Non-Executive Director Apr 2009
Dr Cumming has over 20 years experience in the healthcare and biotechnology market. His roles have progressed from research to sales and marketing roles through to Managing Director level and Board seats. Previously Managing Director of Roche Diagnostic Systems - Oceania Regional Centre, where he transformed a loss making business to one achieving over 30% compound annual growth over a four year period. He was also Managing Director and CEO of an Australian-based biotechnology company commercialising a range of products in cancer diagnosis and treatment. During his tenure he was in charge for taking research from Sydney University through to product registration. This involve capital raising, managing Intellectual Property, investor relations and forging links with relevant international partners. Geoffrey is currently a Non-Executive Director of Multiple Sclerosis Research Australia, a not-for profit organisation. He is a Chairman of the Risk Committee.
Dr John (Jack) Andrew Hamilton Non-Executive ChairmanNon-Executive Director Apr 2018
Dr Hamilton has career spans over 30 years in the energy sector. He has held senior positions across the energy sector over the past 15 years which include heading up Australia's resource project as Director North West Shelf Ventures for Woodside Energy Ltd, CEO for a Liquid Natural Gas project in PNG following on from a 21 year career with Shell in both local and international roles. His career gained experience across a range of functions that include strategy development, commercial marketing, mergers/acquisitions, capital raisings, manufacturing operations and project management in the energy and petrochemical sectors. He formerly held directorships with Southern Cross Electrical Engineering Ltd and Antilles Oil and Gas NL. He is a member of the Risk Committee.
Mr Richard Shubrick Martin Non-Executive Director Sep 2005
Mr Martin holds a Bachelor of Business. He practised as a Chartered Accountant for 16 years, 11 as a partner in a medium sized Sydney practice. Mr Martin has been involved with the Company since it was founded by Dr Maeji. He has considerable experience both operationally and advising corporate entities, his work has included complex business structuring and financing, the establishment of international hotels from conception, public listing of companies, management of foreign currency exposure, establishing and operating start up technology companies and the negotiation and implementation on the purchase and sale of enterprises.
Mr Christopher Parker Non-Executive Director Apr 2019
Mr Parker has 20 years of experience in both domestic and international life sciences sectors predominately through a career with Roche Diagnostics (Roche), an internationally pharmaceutical and diagnostics company. In his final role with Roche, before retiring in the second half 2017, he was Managing Director for UK & Ireland and Management Centre European Agents where he had been in charge for all diagnostic products in the Roche portfolio. Prior to this he held roles in general management, marketing and business development in Canada, Asia and Australia targeting the centralised laboratory, decentralised point-of-care (POC), molecular diagnostics and applied sciences markets.
Mr Duncan P Cornish Chief Financial OfficerCompany Secretary Feb 2019
-
Mr Derek Thomson Chief Executive Officer Aug 2019
-
Derek Thomson Chief Executive Officer
-
Duncan P Cornish Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Levenson Investments Pty Ltd <Levenson Investment A/C> 87,298,315 5.20%
First Cape Management Pty Ltd 52,061,083 3.10%
Marcolongo Nominees Pty Ltd <Marcolongo Super Fund A/C> 41,524,258 2.50%
Fossil Super Pty Ltd <Fossil Fund A/C> 32,400,000 1.90%
Bond Street Custodians Limited <Antsm1 - D67076 A/C> 29,451,081 1.80%
Jackjen Pty Ltd <J A Hamilton Super Fund A/C> 24,131,775 1.40%
Austcorp No 190 Pty Ltd 23,846,877 1.40%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 22,601,847 1.40%
Computer Visions Pty Ltd <Visionary Invests S/F A/C> 20,705,767 1.20%
Stydon Capital Pty Ltd 20,542,501 1.20%
Mr Ian Noble & Mrs Annette Noble <Noble Family Retire Fund A/C> 17,810,000 1.10%
Addison Lake Quality Hire Pty Limited 17,540,418 1.00%
Mrs Mary Curtis 14,750,000 0.90%
AWO & CAO Investments Pty Ltd <Awo & Cao Family S/F A/C> 14,678,571 0.90%
Mr Derek Thomson 14,238,396 0.90%
Mcrae Superannuation Pty Ltd <Mcrae Exec Super Fund A/C> 14,000,000 0.80%
Terry & Linden Deavin Super Pty Ltd <T & L Deavin Sf A/C> 13,000,000 0.80%
Mr Claus Kurt Dzalakowski 12,850,000 0.80%
R & F Martin 11,692,297 0.70%
Mr Kiril Dennis Boitcheff & Mrs Suzanne Janet Boitcheff <Seaview Super Fund A/C> 11,500,000 0.70%

Profile

since

Note